BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...

Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful ...

Originally introduced as “the next generation customizable cinema camera” for all types of filmmakers and video professionals, the original PYXIS 6K model quickly established itself as a top option ...

Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...

While we're still waiting for an official release date for the camera, Blackmagic has released the first footage online from the PYXIS 6K. The $3000 Blackmagic 6K is still listed as a 'new item, ...

Paris-London-Singapore-Pune: Pricing Partners (www.pricingpartners.com), the independent revaluation expert and a world leader in mathematical models and analytics for derivatives and structured ...

Pyxis Mobile, the provider of mobile applications for the financial services industry, recently announced the results of a survey it conducted of its Customer Advisory Board on business continuity ...

SINGAPORE: The Maritime and Port Authority of Singapore (MPA) on Monday (Apr 8) launched the first pilot trial for an electric harbour craft charging point at Marina South Pier on Monday (Apr 8), ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month. The Boston biotech is ...